ReviewExpert opinion on investigational drugs2008
Novel targets and new potential: developments in the treatment of inflammation in chronic kidney disease.
Review in Expert opinion on investigational drugs, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 33 citations in OpenAlex.
- Macrophage polarization in innate immune responses contributing to pathogenesis of chronic kidney disease.BMC nephrology · 2020Review
- Medical and Periodontal Clinical Parameters in Patients at Different Levels of Chronic Renal Failure.International journal of dentistry · 2017Article
- Fibroblast growth factor-23: what we know, what we don't know, and what we need to know.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2013Review
- Let them eat during dialysis: an overlooked opportunity to improve outcomes in maintenance hemodialysis patients.Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation · 2013Review
- A disintegrin and metalloenzyme (ADAM) 17 activation is regulated by α5β1 integrin in kidney mesangial cells.PloS one · 2012Article
- Diets and enteral supplements for improving outcomes in chronic kidney disease.Nature reviews. Nephrology · 2011Review
- Racial and ethnic differences in mortality of hemodialysis patients: role of dietary and nutritional status and inflammation.American journal of nephrology · 2011Article
- Insights into nutritional and inflammatory aspects of low parathyroid hormone in dialysis patients.Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation · 2011Review
- Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals.Kidney international. Supplement · 2010Review
- Association of relatively low serum parathyroid hormone with malnutrition-inflammation complex and survival in maintenance hemodialysis patients.Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation · 2010Article
- Upregulation of monocyte/macrophage HGFIN (Gpnmb/Osteoactivin) expression in end-stage renal disease.Clinical journal of the American Society of Nephrology : CJASN · 2010Article
- Severity of hypoalbuminemia predicts response to intradialytic parenteral nutrition in hemodialysis patients.Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation · 2009Article
- Review article: Biomarkers of clinical outcomes in advanced chronic kidney disease.Nephrology (Carlton, Vic.) · 2009Review
- Therapeutic targets to reduce cardiovascular disease in type 2 diabetes.Nature reviews. Drug discovery · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundPatients with chronic kidney disease (CKD) of all stages experience extremely high mortality, with cardiovascular causes accounting for about half of all their deaths. Traditional risk factors such as hypertension, hypercholesterolemia and diabetes mellitus cannot explain the excessively high cardiovascular mortality in CKD. Chronic inflammation is one of the novel risk factors that appear to contribute to the increased mortality seen in patients with CKD. Therapeutic interventions targeting chronic inflammation in CKD may lead to improved outcomes.
objectivesTo describe the role of inflammation in CKD and to review anti-inflammatory pharmacologic therapies that could have a role in its therapy.
methodsA review of the literature was carried out and expert opinion expressed. RESULTS/
conclusionInflammation is a common and significant problem in CKD. There are currently no approved pharmacologic anti-inflammatory therapies in CKD but several agents are being studied in early clinical trials, while others could become viable alternatives in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.